Skip to main content
Premium Trial:

Request an Annual Quote

Sense Biodetection, Cruinn Diagnostics Ink Distribution Deal for COVID-19 Test in Ireland

NEW YORK – Sense Biodetection announced on Wednesday that it has inked a strategic distribution agreement with Cruinn Diagnostics for Sense's COVID-19 test in Ireland.

Cruinn is one of several planned EU distribution partners for the Veros COVID-19 test, Sense Biodetection said in a statement, including Una Health in the UK. Financial and other terms of the deal were not disclosed. 

The single-use test uses a proprietary enzymatic nucleic acid amplification chemistry that does not require an instrument and returns results in 15 minutes. It received CE marking last week and is intended for use in point-of-care settings. 

The Veros COVID-19 test will be the first instrument-free molecular test for COVID-19 to enter the Irish market, Aidan Wearen, Cruinn's head of marketing and sales, noted in a statement.